Rituximab has been proved effective in B-cell lymphomas as a single agent or in combination with chemotherapy. In rare cases, it may cause interstitial lung disease due to potentially fatal pulmonary toxicity. We report a patient who developed severe interstitial pneumonitis after combination of rituximab with cyclophosphamide, vincristine and prednisolone (COP).